GH001-PPD-203 Postnatal depression research study

Postnatal depression is a type of depression that parents can experience after having a baby. Symptoms can include constant sadness, lack of energy and difficulty bonding with your baby.

The purpose of this research study is to test if a new drug can help mothers suffering from postnatal depression

The study will take 1 week to complete and will involve 5 in person visits in London.

Participants will receive compensation up to the amount of £350. Travel and meal expenses will be reimbursed. 

Please contact us at shenna@lindushealth.com if you have any questions. You can view the patient information sheet below.

Participant Information Sheet
Caregiver Information Sheet

‍

Sponsored by

Patrocinado por

Gesponsert von

Opdrachtgever:

GH Research

Participants

Participantes

Teilnehmenden

Deelnemers:

15

People

Personen

Participate by

Participar mediante

Abschlussdatum

Uiterlijke Inschrijving:

February 29, 2024

29.2.2024

29.2.2024

29.2.2024

Study FAQs

Start Survey
Haga clic aquí para participar
Teilnehmen
Klik hier om deel te nemen

Who is the study for? 

Women who: 

  • Have given birth in the last 12 months
  • Are currently experiencing postnatal depression

‍

What is expected of me? 

  1. You will fill out a questionnaire on this website to determine your eligibility. 
  2. If eligible, you will attend a pre-screening call where your medical history will be recorded, and physical and mental health assessments will be conducted. The study team will tell you more about the study, including the new drug that is being tested called GH001. You will have a chance to ask questions.
  3. First visit: Screening visit in London to assess your full eligibility.
  4. Second visit:  baseline assessments will be conducted. If you are breastfeeding, you will be asked to provide a baseline sample of breast milk 
  5. Third visit: The drug being tested, GH001, will be administered. Vital signs will be monitored, and you will complete a questionnaire on your experiences. You will remain in the clinic until the effects of GH001 have worn off
  6. You will have two follow up visits. These will be to check your vitals, bodily functions and to also report your symptoms and severity of depression

What is the benefit for me?

  • You will receive compensation for taking part in this study, up to the amount of £350. 
  • Participating in this study will give you the opportunity to help further research into treatments for postnatal depression 
  • Participating in this study may offer potential therapeutic benefits.

Complete questionnaire to get started.

Start Survey
Haga clic aquí para participar
Teilnehmen
Klik hier om deel te nemen

GH001-PPD-203 Postnatal depression research study

Postnatal depression is a type of depression that parents can experience after having a baby. Symptoms can include constant sadness, lack of energy and difficulty bonding with your baby.

The purpose of this research study is to test if a new drug can help mothers suffering from postnatal depression

The study will take 1 week to complete and will involve 5 in person visits in London.

Participants will receive compensation up to the amount of £350. Travel and meal expenses will be reimbursed. 

Please contact us at shenna@lindushealth.com if you have any questions. You can view the patient information sheet below.

Participant Information Sheet
Caregiver Information Sheet

‍

Click here to take part
Haga clic aquí para participar
Teilnehmen
Klik hier om deel te nemen

Study for

Estudio dirigido a

Zielgrupper der Studie

Onderzoek voor:

Mothers who have given birth in the last 12 months and who are suffering from postnatal depression.

Sponsored by

Patrocinado por

Gesponsert von

Opdrachtgever:

GH Research

Participants

Participantes

Teilnehmenden

Deelnemers:

15

People

Personen

Participate by

Participar mediante

Abschlussdatum

Duur van onderzoek:

February 29, 2024

29.2.2024

29.2.2024

29.2.2024

Who is the study for? 

¿A quién va dirigido el estudio?

Für wen ist die Studie geeignet?

Voor wie is het onderzoek bedoeld?

Women who: 

  • Have given birth in the last 12 months
  • Are currently experiencing postnatal depression

‍

What is expected of me? 

¿Qué se espera de mí?

Was wird von mir erwartet?

Wat wordt van mij verwacht?

  1. You will fill out a questionnaire on this website to determine your eligibility. 
  2. If eligible, you will attend a pre-screening call where your medical history will be recorded, and physical and mental health assessments will be conducted. The study team will tell you more about the study, including the new drug that is being tested called GH001. You will have a chance to ask questions.
  3. First visit: Screening visit in London to assess your full eligibility.
  4. Second visit:  baseline assessments will be conducted. If you are breastfeeding, you will be asked to provide a baseline sample of breast milk 
  5. Third visit: The drug being tested, GH001, will be administered. Vital signs will be monitored, and you will complete a questionnaire on your experiences. You will remain in the clinic until the effects of GH001 have worn off
  6. You will have two follow up visits. These will be to check your vitals, bodily functions and to also report your symptoms and severity of depression

Contact our study team
shenna@lindushealth.com

What is the benefit for me?

¿En qué me beneficia?

Welchen Nutzen habe ich davon?

Wat is het voordeel voor mij?

  • You will receive compensation for taking part in this study, up to the amount of £350. 
  • Participating in this study will give you the opportunity to help further research into treatments for postnatal depression 
  • Participating in this study may offer potential therapeutic benefits.

Complete this questionnaire to take part.

Fülle diesen Fragebogen aus, um herauszufinden, ob Du berechtigt bist

Click here to take part
Teilnehmen
Get in touch
HomePlatformParticipantsCase StudiesNewsAboutCareersGlossaryContact Us